Every 10-Q that INTEGRATED BIOPHARMA INC (INBP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INBP filings page.
Integrated BioPharma, Inc. reported weaker results for the quarter and nine months ended March 31, 2026, driven by lower volumes and margin pressure. Net sales for the nine-month period fell to $34,076 from $40,178, a 15.2% decline, with Contract Manufacturing and Other Business Lines both down.
The company swung to a nine‑month operating loss of $1,836 from operating income of $1,431, and posted a net loss of $1,476 versus prior‑year net income of $986. For the March quarter, sales declined 27.5% to $10,107, producing a gross loss and net loss of $837.
Customer concentration remains high: two Contract Manufacturing customers accounted for about 90% of consolidated net sales, led by Life Extension and Herbalife. Despite the downturn, cash improved to $5,826 and working capital was about $12,447, supported by an undrawn revolving credit facility of roughly $4,500. Management highlights inflation, tariffs and labor costs as ongoing margin headwinds.
Integrated BioPharma, Inc. reported weaker results for the quarter and six months ended December 31, 2025, as lower sales and thinner margins led to losses. Quarterly net sales fell to $11.3 million from $12.6 million, and the company swung to a net loss of $0.8 million versus prior-year profit.
For the six-month period, net sales declined to $24.0 million from $26.2 million, while net income of $0.4 million a year earlier turned into a net loss of about $0.6 million. Gross margin compressed significantly as cost of sales rose as a percentage of revenue, reflecting lower volumes to cover fixed manufacturing costs and pressure from inflation and labor markets.
The business remains highly concentrated, with two contract manufacturing customers accounting for roughly 89% of six‑month net sales. Despite the loss, liquidity improved: cash increased to $5.3 million, operating cash flow reached $1.9 million, and the company had no borrowings under its up to $4.5 million credit facilities, supporting working capital of about $14.3 million.
Integrated BioPharma (INBP) reported lower quarterly results for the three months ended September 30, 2025. Sales, net were $12,689 (down 6.8% year over year), and gross profit was $1,019 versus $1,371 a year ago as cost of sales rose to 92.0% of sales. Operating income fell to $163 from $490, and net income was $123 compared with $259 in the prior-year quarter.
Customer concentration remained high: two contract manufacturing customers represented 87% of consolidated net sales, with Life Extension at 71% and Herbalife at 20% of segment sales. Operating cash flow improved to $1,301 from $657, lifting cash to $4,732. Working capital was approximately $14,860.
The company had no borrowings and access to a revolving credit facility and a convertible equipment line totaling about $4,500. Management cited inflation and tight labor markets as margin headwinds while keeping selling and administrative expenses near flat.